These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 17438382)

  • 1. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varenicline for smoking cessation: a placebo-controlled, randomized study.
    Wang C; Xiao D; Chan KP; Pothirat C; Garza D; Davies S
    Respirology; 2009 Apr; 14(3):384-92. PubMed ID: 19192221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varenicline in smoking cessation.
    Tonstad S; Rollema H
    Expert Rev Respir Med; 2010 Jun; 4(3):291-9. PubMed ID: 20524911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
    Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P
    Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoking cessation: an overview of treatment options with a focus on varenicline.
    Stack NM
    Pharmacotherapy; 2007 Nov; 27(11):1550-7. PubMed ID: 17963463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varenicline for smoking cessation.
    Tonstad S
    Expert Rev Neurother; 2007 Feb; 7(2):121-7. PubMed ID: 17286546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
    Faessel HM; Gibbs MA; Clark DJ; Rohrbacher K; Stolar M; Burstein AH
    J Clin Pharmacol; 2006 Dec; 46(12):1439-48. PubMed ID: 17101743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longer course of varenicline therapy improves smoking cessation rates.
    Lee JH; Jones PG; Bybee K; O'Keefe JH
    Prev Cardiol; 2008; 11(4):210-4. PubMed ID: 19476573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
    Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
    Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
    Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
    Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varenicline: new drug. Smoking cessation: no better than nicotine.
    Prescrire Int; 2006 Dec; 15(86):210-2. PubMed ID: 17165237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S
    J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
    Foulds J
    Int J Clin Pract; 2006 May; 60(5):571-6. PubMed ID: 16700857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness and safety of varenicline for smoking cessation].
    Christalla P; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New drugs; varenicline].
    van Bronswijk H; Dubois EA; Zitman FG; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2503-4. PubMed ID: 18062594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.